Objective-Skin autofluorescence (SAF), a measure of advanced glycation end product accumulation, is associated with kidney function. We investigated the association of SAF with rate of kidney function decline in a cohort of patients with peripheral artery disease. Approach and Results-We performed a post hoc analysis of an observational longitudinal cohort study. We included 471 patients with peripheral artery disease, and SAF was measured at baseline. Primary end point was rate of estimated glomerular filtration rate (eGFR) decline. Secondary end points were incidence of eGFR <60 and <45 mL/min/1.73 m 
A dvanced glycation end products (AGEs) are irreversibly glycated proteins with injurious effects on tissues. 1 AGE formation is promoted by hyperglycemic environments and oxidative stress and has previously been associated with aging, diabetes mellitus (DM), chronic kidney disease (CKD), and cardiovascular disease. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Accumulation of AGEs on long-lived proteins such as collagen occurs in all types of tissue, including the skin, vascular tissue, and glomerular and tubular basement membranes. Increased levels of AGEs contribute to tissue injury by activating proinflammatory and pro-oxidative pathways, which can cause kidney damage. 7 In turn, reduced glomerular filtration rate causes a lower rate of AGE excretion, leading to a vicious cycle of further AGE accumulation and more kidney and cardiovascular damage. 7 AGE accumulation has been and is currently being investigated as a treatment target using different approaches such as diet, improved glucose control, and specific AGElowering drugs. [14] [15] [16] Skin autofluorescence (SAF), measured noninvasively with an optical device, is a validated technique to assess AGE levels in the skin. 17 Peripheral artery disease (PAD) is associated with an increased risk of CKD. 18 Previously, we showed that SAF is elevated in subjects with PAD and is associated with mortality, cardiovascular events, and amputation during follow-up. 10, 12, 13 The association of SAF and CKD has also previously been demonstrated. 19 SAF was also found to be associated with development of albuminuria in a cohort of patients with type 2 DM. 20 SAF may therefore be a noninvasive measure to predict kidney disease progression. Because both CKD and DM increase SAF, there may be an interaction between CKD and DM in the relationship with SAF. Therefore, we investigated the associations of the presence of impaired kidney function and DM with SAF at baseline. Furthermore, we assessed the association of baseline SAF with rate of kidney function decline during follow-up. For this study, we used data of an observational cohort study that included patients with PAD. We hypothesized that increased SAF levels are independently associated with impaired kidney function and DM at baseline and with accelerated kidney function decline during follow-up.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
In short, we performed a post hoc analysis of a single-center prospective cohort study of 471 patients with established PAD. Deposition of tissue AGEs was noninvasively measured by SAF with the AGE reader. Five-year follow-up data were analyzed. The primary end point was rate of estimated glomerular filtration rate (eGFR) decline, defined as the change in eGFR in mL/min/1.73 m 2 /y. For the longitudinal data analysis of the primary end point, we performed a linear mixed model analysis with the repeated measurements of eGFR as the outcome and a random effect for time, to allow for individual deviations to the overall population slope. Patients with at least 2 eGFR measurements were included in this analysis. All models included SAF and an interaction term between SAF and time, to allow for assessment of differences in change in eGFR over time across SAF levels (SAF×time). Covariates that were significant in the cross-sectional multivariable analysis with SAF were included in the linear mixed model. Three models were tested: model 1, crude model including SAF, time, and their interaction term; model 2, as model 1 plus age and sex; and model 3, as model 2 plus smoking status and DM status. Secondary end points were incidence of eGFR <60 mL/ min/1.73 m 2 , <45 mL/min/1.73 m 2 and rapid eGFR decline, defined as an eGFR decline of >5 mL/min/1.73 m 2 /y. A Cox proportional hazards regression analysis was used to assess the association of SAF with incidence of eGFR <60 mL/min/1.73 m 2 and <45 mL/min/1.73 m 2 , and logistic regression analysis assess the association between SAF and rapid eGFR decline (coded as categorical variable).
Results

Baseline Characteristics
Baseline characteristics are presented in Table 1 for the overall cohort and for participating subjects stratified according to SAF tertiles (<2.5, 2.5-3.1, and >3.1 arbitrary units [AU]). Mean SAF was 2.8±0.7 AU and mean age was 65.9±10.6 years, 70% were men, and 31% had DM. Baseline eGFR was 76.9±21.5 mL/min/1.73 m 2 . Patients with higher SAF levels were older; more frequently had DM, a history of coronary artery disease, and cerebrovascular disease; used β blockers and diuretics more often; had higher hemoglobin A1c (HbA1c) levels and lower eGFR (all P<0.05; Table 1 ).
Cross-Sectional Analysis of Covariates Associated With SAF
Evaluation of covariates possibly associated with SAF is shown in Table 2 . Univariable and multivariable linear regression analyses showed significant associations of SAF with several covariates. In the multivariable analysis, higher levels of SAF were independently associated with being older, smoking, having DM, and having impaired kidney function. Figure 1 shows the association of baseline DM status and impaired kidney function (eGFR above and below 60 mL/ min/1.73 m 2 ) with SAF and indicates that SAF levels are dependent on presence of DM and impaired kidney function (P<0.001). No significant interaction was found between DM status and impaired kidney function versus SAF level (P for interaction 0.6), suggesting that DM and impaired kidney function are truly independently associated with SAF. A sensitivity analysis replacing hypertension, hypercholesterolemia, obesity, impaired kidney function, and DM status with baseline systolic blood pressure, total cholesterol, eGFR, and HbA1c levels is shown in Table I in the online-only Data Supplement. This analysis showed similar associations of SAF with age, smoking status, HbA1c, and eGFR. In the univariable analysis, the P value for total cholesterol met the threshold for entering the multivariable analysis (P=0.06 for total cholesterol versus P=1.0 for hypercholesterolemia in the original analysis). However, in the multivariable analysis, no significant association of cholesterol with SAF was found.
Longitudinal Analysis of SAF and eGFR Decline
During a median follow-up of 3.0 years (interquartile range, 1.5-4.7 years), patients had on average 7.4 eGFR measurements available (range, 1-81 measurements), with a median interval of 0.5 years (interquartile range, 0.3-1.1). Twentyone patients without follow-up eGFR measurements were excluded from the longitudinal analysis. The overall eGFR slope for the remaining 443 patients was −1.8±4.4 mL/ min/1.73 m 2 /y. Seventeen patients (4%) had a doubling of serum creatinine during follow-up.
The linear mixed model analysis of SAF as continuous variable with the repeated eGFR measurements as outcome showed that although patients with higher SAF levels had on average a lower eGFR at baseline (−6.5 mL/min/1.73 m 2 per 1 AU increase in SAF [95% confidence interval, −9.4 to −3.6]; P<0.001), the interaction term between SAF and time was not significant (P=0.8; Table 3 ). This indicates that eGFR slopes during follow-up across SAF levels at baseline did not differ. Across SAF tertiles, there was also no difference in eGFR slope: for tertile 1 (SAF, <2.5 AU), −1.8±2.2; for tertile 2 (SAF 2.5-3.1 AU), −1.7±2.4; and for tertile 3 (SAF >3.1 AU), −2.1±2.0 mL/min/1.73 m 2 /y (P=0.6 from linear mixed model analysis for both tertiles 2 and 3 versus tertile 1; Figure 2 ). The sensitivity analyses showed that patients with DM did not have a faster decline in eGFR than patients without DM (P=0.1; Table II in the online-only Data Supplement). Additionally, the interaction between SAF, DM, and time was also not significant (P=0.5), meaning that patients with DM and high levels of SAF did not have faster eGFR decline than patients without DM and lower levels of SAF. Lastly, to show the robustness of our results, we performed a linear regression analysis studying SAF levels across tertiles of eGFR change. No differences in SAF levels were found (P=0.1 for trend; For the secondary outcomes (incidence of eGFR <60 and <45 mL/min/1.73 m 2 ), 107 and 42 patients, respectively, already had eGFR below these thresholds at baseline and were excluded. During follow-up, 77 patients (16%) reached an eGFR <60 mL/min/1.73 m 2 and 54 patients (11%) reached an eGFR <45 mL/min/1.73 m 2 . Kaplan-Meier figures for both end points are shown in Figure I in the online-only Data Supplement. The figures show significant differences in event-free survival for both incident eGFR <60 mL/min/1.73 m 2 (log-rank P=0.02) and incident eGFR <45 mL/min/1.73 m 2 (log-rank P=0.002). The hazard ratios for all Cox regression models tested for both end points are listed in Table IV in the online-only Data Supplement. Per unit increase in SAF, patients had a 54% higher risk of developing eGFR <60 mL/ min/1.73 m 2 (hazard ratio, 1.54; 95% confidence interval, 1.13-2.10; P=0.006) and a 76% higher risk of developing eGFR <45 mL/min/1.73 m 2 (hazard ratio, 1.76; 95% confidence interval, 1.20-2.59; P=0.004). However, this association lost significance for both end points after adjusting for age and sex in model 2. The associations between SAF and both end points remained not significant in model 3.
Finally, we studied the association between baseline SAF and rapid kidney function decline during follow-up. A total of 104 patients had an eGFR decline of >5 mL/min/1.73 m 2 /y. Results of the logistic regression analysis are listed in Table  V in the online-only Data Supplement. The logistic regression showed no association between SAF and rapid kidney function decline in all models (P>0.05). AU indicates arbitrary unit; BMI, body mass index; CCB, calcium-channel blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin-aldosterone system; SAF, skin autofluorescence; and SBP, systolic blood pressure.
Discussion
Our results indicate that in patients with PAD, both DM and impaired kidney function were associated with increased AGE accumulation, measured as SAF. In a multivariable analysis of the cross-sectional data, higher SAF levels were significantly associated with lower eGFR independent of age, smoking status, and DM status. However, in longitudinal analyses, we found no independent association of baseline SAF levels with eGFR decline during follow-up, incidence of eGFR <60 mL/ min/1.73 m 2 or eGFR <45 mL/min/1.73 m 2 , or rapid eGFR decline. Furthermore, we found no interaction between SAF and DM on eGFR decline.
The finding that SAF is cross-sectionally associated with impaired kidney function confirms the findings of earlier studies. 20, 21 However, the longitudinal analyses in our cohort showed no association between SAF and eGFR decline. Only one study has previously investigated the relationship between SAF and kidney function outcome. That study showed, in a cohort of 449 Japanese predialysis CKD patients with a 32% DM prevalence, that SAF predicted the rate of kidney function decline and incidence of end-stage kidney disease. 11 The discrepant findings in our study versus those in the study by Tanaka et al 22 may be because of population differences between the cohorts. For whites, the reference value of SAF in healthy individuals is 2.46±0.57 for the age group of 60 to 70 years, and SAF has been shown to increase with ≈0.023 AU per year. Our cohort had a mean SAF of 2.8 AU versus 2.1 AU in the other cohort, suggesting that our cohort was in poorer health. In addition, the other study included only Japanese patients, whereas we included Dutch patients. Others have shown in a large cohort of CKD patients from 3 different ethnic origins (white, Oriental Asian, and South Asian) that both Asian groups had faster progression toward end-stage kidney disease than the white group. 23 In addition, the subjects from the Tanaka cohort were selected to have CKD. In line, average baseline eGFR was 55.8 mL/min/1.73 m 2 , whereas in our study it was 76.9 mL/min/1.73 m 2 , although age was similar in the 2 cohorts (64.0 and 65.9 years, respectively). Subjects with lower eGFR are known to have a higher risk for adverse kidney outcomes during follow-up. 24 Indeed, in the Tanaka study, 11% reached end-stage renal disease or doubling of serum creatinine during follow-up, and this figure was considerably lower in our cohort. The more rapid rate of eGFR decline in the Asian cohort may have increased the sensitivity for finding significant associations between SAF and kidney end points. Furthermore, it is known that AGEs accumulate in case of impaired kidney function, creating a vicious cycle of AGE accumulation, leading to further kidney damage with even more reduced excretion of AGEs, and further AGE accumulation. 7 Given the difference in baseline eGFR between our cohort and the Japanese cohort and our discrepant findings, it is possible that this vicious cycle only occurs in established CKD with eGFR levels below a certain threshold.
Our cohort had a high prevalence of (severe) cardiovascular comorbidity, which is independently associated with SAF, 10, 25 but most patients had preserved kidney function. Furthermore, others have shown that SAF serves as a marker of metabolic memory, reflecting glycemic and renal status during the past 10 years. 26 We found a significant cross-sectional association of SAF with eGFR but did not find an association of SAF with eGFR decline. Additionally, there was no interaction between SAF and DM on eGFR decline. It is therefore possible that SAF is merely a marker of impaired kidney function and metabolic memory and not a risk factor for further kidney function decline.
A limitation of our study is that SAF was measured only at baseline. Furthermore, data on albuminuria were not available. However, it may be expected that additional adjustment for albuminuria could only have weakened the association between SAF and kidney function decline in our analyses. Lastly, creatinine was only measured on indication by regular medical caregivers of the patients included in our cohort. This may have resulted in bias, with relatively more information on eGFR during follow-up being available in patients at highest risk for kidney function decline. However, because this bias would lead to a higher chance of finding a significant association of SAF with kidney function decline, this only strengthens our negative findings. Strengths of this study were that we investigated a relatively large cohort and that longitudinal associations of SAF with eGFR slopes have not been investigated before in a white cohort.
Given the presently available findings, the future of SAF as a potential risk factor for adverse renal outcome and as a screening tool to identify subjects at risk for accelerated kidney function decline remains unclear. We found no association of SAF with eGFR decline in patients with PAD, which conflicts with earlier findings that showed a significant association of SAF with eGFR decline in patients with established CKD.
11 Therefore, the use of SAF as a predictor of kidney function decline may be limited to patients without cardiovascular comorbidity or SAF may only be a predictor in patients with established CKD. Further research is needed to clarify if, and in which populations, SAF can predict kidney function decline. Such studies should preferably include mixed populations to allow within-study subgroup analyses. In addition, to our knowledge, it has not been investigated whether serial measurements of SAF may further improve the calculation of cardiovascular or kidney risk. It may be that changes in SAF are more strongly associated with eGFR decline than a single SAF measurement.
In conclusion, in this cohort of patients with PAD, elevated SAF was associated with lower eGFR levels at baseline. Although SAF has previously been established as a predictor for cardiovascular disease and mortality, it did not predict the rate of kidney function decline during follow-up.
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